博九娱乐网

Mural Oncology is leveraging its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. By combining their expertise in cytokine biology and immune cell modulation and their protein engineering platform, they are developing medicines to deliver meaningful and clinical benefits to people living with cancer. Their mission is to broaden the…More potential and reach of cytokine-based immunotherapies to improve the lives of patients. Their lead candidate, nemvaleukin, is currently in potentially registrational trials in mucosal melanoma and platinum-resistant ovarian cancer. Mural Oncology has its registered office in Dublin, Ireland, and its primary facilities in Waltham, Mass.